FNDC5 and Cirrhosis: There are data that confirm the impact of conditions such as insulin resistance, chronic inflammation, cirrhosis, or arteriosclerosis on the increased production of MSTN antagonists such as irisin, follistatin, or IGF-1 [59,63,64,65].